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Abstract 
Acute kidney injury (AKI) is common in critically ill patients and associated with grim short- and long-term outcome. 
Although in the vast majority of cases AKI is multifactorial, with sepsis, shock and nephrotoxicity accounting for most 
episodes, specific causes of AKI are not uncommon. Despite remaining uncertainties regarding their prevalence in the 
ICU, prompt recognition of specific aetiologies of AKI is likely to ensure timely management, limit worsening of renal 
dysfunction, and ultimately limit renal and systemic consequences of AKI. The ability to recognize conditions that 
may be associated with specific aetiologies and the appropriate use of clinical imaging, biological and immunological 
tests, along with optimal assessment of the need for renal biopsies, should be part of routine ICU care. In this review, 
we summarize uncertainties, current knowledge and recent advances regarding specific types of AKI. We describe the 
most common specific causes as well as rare aetiologies requiring urgent management, and outline available tools 
that may be used during the diagnostic work-up along with their limitations.
Keywords: Acute kidney injury, Diagnostic techniques and procedures, Glomerular filtration rate, Kidney function 
tests, Biopsy, Intensive care unit
Introduction
Acute kidney injury (AKI) can portend an incremen-
tal risk for short- and long-term complications includ-
ing fatal outcome [1], nephron loss along with risk of 
chronic kidney disease (CKD) or end-stage kidney dis-
ease (ESKD) [2]. In intensive care unit (ICU) settings, up 
to 60% of patients develop AKI and up to 12% of patients 
require renal replacement therapy (RRT) [1]. Although 
the vast majority of AKI is multifactorial, with sep-
sis, shock and nephrotoxicity accounting for most epi-
sodes [1, 3], it is important to remember that critically 
ill patients may also present with specific types of AKI 
requiring targeted diagnostic work-up and treatment.
In this review, we will summarize uncertainties, cur-
rent knowledge and recent advances regarding specific 
types of AKI, and outline available tools that may be used 
during the diagnostic work-up.
Diagnosis of AKI and Input of biomarkers
The Kidney Disease Improving Global Outcomes 
(KDIGO) guideline defines AKI as an abrupt decrease 
of kidney function over a period of 7 days or less based 
on a rise in serum creatinine or an episode of oliguria 
[4]. For patients whose renal function returns to base-
line within 48  h, the Acute Disease Quality Initiative 
(ADQI) 16 conference proposed to use the term “rapid 
reversal” of AKI, while “persistent AKI” is characterized 
by a duration beyond 48 h [5]. In patients with persistent 
AKI, it is essential to determine its underlying aetiology. 
In addition, it is recommended to evaluate the haemody-
namic and volume status, and to identify complications 
that may indicate the need for RRT. A period of renal 
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dysfunction that persists for >7  days is categorized as 
Acute Kidney Disease (AKD) [4, 5], and the term Chronic 
Kidney Disease (CKD) is used for patients with kidney 
disease persistent after 90 days [4, 5].
The KDIGO definition for AKI is based on creatinine 
and oliguria, two imperfect markers. Other biomarkers 
may indicate kidney damage earlier than conventional 
biomarkers. At present, two kidney damage biomark-
ers are available for clinical use: neutrophil gelatinase-
associated lipocalin (NGAL) can be measured in urine 
and blood, and the combination of urinary insulin-like 
growth factor-binding protein 7 (IGFBP7) and tis-
sue inhibitor of metalloproteinases 2 (TIMP-2) can be 
measured using the  NephroCheck® point of care device. 
Although the use of these biomarkers might allow earlier 
AKI detection [6–8], their performance is limited and 
their impact on relevant patient or kidney outcomes is 
uncertain, as is their usefulness for other endpoints such 
as use of RRT and long-term kidney outcomes [9].
Although the importance of differentiating functional 
volume-responsive AKI from intrinsic parenchymal 
diseases is classically emphasized, several studies have 
pointed out the frequent coexistence of intrinsic and 
pre-renal injury in critically ill patients [10–14]. This 
translates into poor performance of urinary indices and 
limited performance of kidney damage markers in pre-
dicting volume-responsive AKI [10–14]. Urine sediment 
analysis remains, however, mandatory to detect proteinu-
ria, haematuria, leukocyturia or eosinophiluria, that may 
suggest specific causes of AKI.
Clinical imaging
Renal imaging is a mandatory component of AKI diag-
nostic work-up. Depending on the technique, it enables 
to evaluate organ morphology and provides insights in 
function, perfusion and possibly aetiology.
Ultrasonography
Renal ultrasonography (US) represents the first-line 
imaging modality in most cases of AKI [15, 16]. It is inex-
pensive, non-invasive, widely available, can be performed 
at the bedside and may influence further investigations 
and management.
Conventional (B‑mode) imaging
Conventional (B-mode) is the basic examination mode. 
It generates grey-scale images based on the property of 
sound waves to reflect at interfaces of media of different 
densities. This mode permits the evaluation of longitudi-
nal size and parenchyma echogenicity and demonstrates 
(or rules out) the presence of hydronephrosis or cysts.
Kidney size is typically measured in its long axis 
(bipolar length). Normal values range from 9 to 12 cm 
according to patient size and gender. Small kidney size 
is suggestive of underlying CKD, while enlarged kid-
neys might be observed in infiltrative diseases, renal 
vein thrombosis or acute rejection in transplanted 
kidneys.
Renal echogenicity is evaluated by comparison with 
that of adjacent tissues (liver or spleen). Decreased echo-
genicity can be physiologic but might be associated with 
pathological processes such as oedema. Hyperechogenic-
ity almost always indicates diffuse kidney parenchymal 
pathology (infiltrative diseases, inflammatory states). 
Chronic kidney disease is often associated with increased 
brightness since fibrous tissues increase echogenicity.
Urinary tract obstruction represents a relatively eas-
ily reversible cause of AKI. Although less commonly 
encountered in ICU patients, it should be ruled out in all 
patients with AKI with suggestive history or lack of clear 
causes of AKI. On US, the collecting system of the kidney 
is not normally visible unless significant hydronephrosis 
is present. Hypovolemia, early obstruction and retrop-
eritoneal tumours or fibrosis may lead to false negative 
results. False positive findings can be observed in preg-
nancy and in patients with diabetes insipidus, vesico-
ureteral reflux, megacystis-megaureter syndrome, full 
bladder and urinary tract infection.
Although unrelated to AKI, cysts are often encountered 
on renal US examination. Benign cysts are well deline-
ated with a clear content, while complex cysts contain 
septa or wall thickening. Solid masses are usually neo-
plastic. Specialist referral is required when such images 
are encountered.
Doppler‑based resistive indices (RI)
Adding Doppler technology to grey-scale images enables 
visualization of intra-renal vasculature and computa-
tion of dynamic parameters. The most studied of those is 
the intra-renal resistive index (RI). RI can be calculated 
based on two parameters of flow (the peak systolic shift 
and minimum diastolic shift) which can be measured in 
the arcuate or interlobar arteries in pulsed wave Doppler 
mode [RI = (peak systolic velocity − end diastolic veloc-
ity)/peak velocity]. Renal RI is a simple, non-invasive tool 
easy to use at the patient bedside (Fig.  1). It has been 
shown to have an excellent inter-observer reproducibil-
ity but limited precision [17]. RI is considered normal if 
<0.70; however, the normal RI range is age-dependent 
[18].
Unfortunately, the physiological and clinical sig-
nificance of RI remain debated. Initially considered an 
indicator of renal vascular resistance and blood flow, 
changes in RI have been proposed to help titrate nor-
epinephrine to better tailor mean arterial pressure in 
ICU patients [19]. However, in vivo and in vitro studies 
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have suggested a correlation with vascular compliance 
(vascular distensibility) [18]. In addition, RI is largely 
influenced by extra-renal factors such as cardiac output, 
heart rate,  PaCO2 and  PaO2, and renal interstitial and 
intra-abdominal pressures [18]. As a result, the use of 
RI for AKI diagnosis is currently not recommended and 
further studies are required to establish its role in clini-
cal practice [20].
Contrast‑enhanced ultrasonography (CEUS)
CEUS is a newer ultrasound-based imaging modality 
that utilizes dedicated US contrast agents. US contrast 
agents are made of gas microbubbles, which act as potent 
ultrasound reflectors. Commercially available prepara-
tions have high stability and very small-sized microbub-
bles. They are injected into the peripheral vein and can be 
visualized in arteries and capillaries. As such, CEUS ena-
bles delicate visualization of organs’ macro- and micro-
circulation (Fig.  2). Cortical necrosis can be detected 
using CEUS. Methods have been proposed to use CEUS-
derived techniques to measure organ perfusion. These 
methods have been validated in animal models and 
healthy volunteers [21]. To date, there are limited data 
on its possible utilization in critically ill patients. Stud-
ies have shown that CEUS was feasible and safe in such 
contexts [22] but with potentially conflicting results [23]. 
Further research is required to establish the role of CEUS 
in ICU.
Fig. 1 Results of a renal colour-Doppler ultrasonography showing 
renal vascularization (a). RI measurement using pulsed wave Doppler 
(b) [18]
Fig. 2 Examples of renal contrast-enhanced ultrasound images: with direct application of the US probe on the kidney (a) or in a critically ill patient 
(b)
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Computerized tomography (CT)
CT is increasingly used in the ICU. Despite the potential 
nephrotoxicity of iodinated contrast agents, in patients 
with septic AKI, contrast CT may be necessary to iden-
tify the source of sepsis. Non-contrast CT remains the 
gold standard for the diagnosis of urolithiasis and com-
plicated pyelonephritis. It enables detection of underly-
ing renal or abdominal abnormalities in patients with 
AKI (cysts, renal carcinoma, aortic aneurysms, etc.) and 
detection of hydronephrosis. Finally, last generation 
triphasic CT (functional CT), can allow assessment of 
GFR and renal blood flow, but the exact role in critically 
ill patients needs to be determined in future studies [24].
Magnetic resonance imaging (MRI)
MRI techniques allow detailed assessment of renal anat-
omy, tumors and infections. Some techniques enable 
quantification of renal perfusion and differentiation 
between cortical and medullar areas. Unfortunately, 
these techniques require the injection of gadolinium, 
which has been associated with the risk of nephrogenic 
systemic fibrosis in patients with altered renal function 
[25]. Non-contrast methods such as cine-contrast MRI 
or BOLD MRI have been proposed and tested in criti-
cally ill patients [26]. To date, given the cost, availability 
and length of the protocols, MRI does not play a role in 
the routine diagnostic workup of AKI outside research 
studies.
Renal biopsy in the intensive care setting
Given that the common heterogeneity in causes of AKI, 
histological diagnosis is often not considered, and indeed 
renal biopsy, despite being an essential tool in non-crit-
ical care nephrology, is rarely performed. However, as 
outlined above, there are specific situations where his-
topathological diagnosis does deserve consideration. In 
spite of the improved AKI recognition and assessment 
of severity provided by recently developed scoring sys-
tems such as KDIGO, recent evidence demonstrates a 
lack of correlation between KDIGO classification and 
actual AKI aetiology [27]. These studies emphasize that 
kidney biopsy should be considered more frequently than 
currently employed in order to better understand AKI 
and avoid missing specific causes of AKI and treatment 
opportunities to reduce the risk of subsequent CKD.
Indications in the ICU
Although the common causes of AKI within the ICU can 
be diagnosed clinically without histological confirmation, 
the presumptive diagnosis risks ignoring treatable condi-
tions such as acute interstitial nephritis (AIN). Occasion-
ally, AKI may be due to a specific multi-systemic disorder 
or conditions fulfilling standard indications for renal 
biopsy such as nephritic and/or nephrotic syndrome, or 
rapidly progressive AKI of unclear aetiology. Although 
renal biopsy should probably be discussed after initial 
diagnostic work-up in patients with AKI without obvious 
aetiologies or in patients with renal parenchymal disease, 
clinicians must ensure that the benefits of renal biopsy 
outweigh the risks. Thus, renal biopsy is usually not done 
if the expected histological findings are assumed neither 
to guide a specific treatment nor to determine a change 
in treatment. Main indications for renal biopsy in the 
critically ill patient include persistent loss of kidney func-
tion, proteinuria greater than 3 g/day or a clinical picture 
suggestive of systemic disease [28].
Precautions and contraindications
Careful patient selection as well as the use of real-time 
US has minimized the risks associated with percutaneous 
renal biopsy, but it does carry a morbidity and mortality 
risk [29]. Significant complications include haemorrhage, 
infection and arteriovenous fistula formation occurring 
in 3–13% of cases and a mortality risk of up to 0.2% [30]. 
Although controlling blood pressure for preventing com-
plications has not been firmly demonstrated, maintaining 
blood pressure under 140/90 mmHg on the day of renal 
biopsy is a classical objective. Haemostatic abnormali-
ties and particularly a decreased platelet count have been 
reported to be associated with higher complication rates 
[31], but whether there is a role for routinely measuring 
bleeding time and administering desmopressin prior to 
renal biopsy remains a matter of debate. In patients with 
coagulation disorders or taking anticoagulants or anti-
platelet treatment, we suggest managing patients accord-
ing to national guidelines on perioperative management 
of patients at high risk of bleeding. The “classic” contrain-
dications to renal biopsy are outlined in Table 1.
Technique
Renal biopsy can be performed at the bedside under real-
time US guidance in a patient placed in the prone posi-
tion. It should only be done by clinicians that are expert 
Table 1 Usual contra-indications to percutaneous biopsy
NOACs new oral anticoagulants
Relative contraindications Absolute contraindications
Use of antiplatelet drugs Active urinary sepsis
Use of NOACs Hydronephrosis
Solitary kidney Uncontrolled hypertension
Small kidneys Bleeding diathesis
Renal malignancy
Widespread cystic disease
Uncooperative patient
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in performing the procedure. In patients on mechani-
cal ventilation, a ventilator pause can be used to stop 
kidney movement with respiration. Non-percutaneous 
renal biopsy techniques may be considered where there 
are absolute contraindications to the percutaneous tech-
nique. These include open renal biopsy [32], laparascopic 
approach [33] and transjugular approach, the latter car-
rying the risk of inadequate tissue sampling [34]. This is 
relevant in that renal biopsy findings must be interpreted 
in the clinical context and in tandem with laboratory 
features, as prognostication based upon renal pathology 
alone is affected by the sample size and may be less accu-
rate in biopsies with few glomeruli (i.e. ≤5).
Renal biopsy on the ICU: experience
Only two studies, both from France, have examined the 
impact of renal biopsy in the critically ill. Augusto et al. 
preformed a multicentre retrospective analysis over a 
10-year period from ten ICUs [31]. Among 77 patients 
who underwent a renal biopsy (88% on native kidneys), 
50% of non-transplanted patients had a specific diagno-
sis including glomerulonephritis (22%), acute vascular 
nephritis (10%), AIN (3%), and deposit disease (3%) [31]. 
The occurrence of AKI before hospital admission, the 
presence of clinical extra-renal signs, and the absence of 
classical contributory factors of acute tubular necrosis 
were associated with renal biopsy yielding a specific diag-
nosis [31]. In this study, one-fifth of the non-transplanted 
patients had their treatment modified and one-sixth had 
a specific treatment stopped. Similarly, Philipponnet 
et  al. described a retrospective multicenter study over 
10 years in five French ICUs. Of the 54 kidney biopsies 
preformed, acute tubular necrosis was found in 46%, glo-
merulonephritis in 25%, acute vascular nephritis in 20%, 
AIN in 10%, and deposit disease in 5% [28]. Of note, in 
most cases, interstitial nephritis had not been suspected 
prior to renal biopsy, and renal biopsy results contributed 
to the management in over 70% of cases [28].
Interestingly, in both studies, biopsy findings confirmed 
clinical suspicion, suggesting a selection bias which may 
have contributed to the high diagnostic and therapeu-
tic contribution. Patient inclusion in these cohorts was 
highly selective with biopsies performed in less than 
1% of patients with AKI on ICU, and as such no recom-
mendations can be drawn as to who may require biopsy. 
It must be noted, however, that in both these studies 
complications related to biopsy were more frequently 
observed in ICU patients when compared to the reported 
incidences in nephrology patients, including a high risk 
of severe and even fatal bleeding [28, 31].
These studies demonstrate that in highly selected cases 
renal biopsy may carry meaningful and clinically rel-
evant information at a cost of significant risk of severe 
complications. Most patients underwent a percutaneous 
procedure, and it remains unclear whether complica-
tions could have been prevented by using a transjugular 
approach. Similarly, it is also possible that the develop-
ment of new biomarkers or techniques to image renal 
injury will reduce the need for renal biopsies [35].
Acute kidney injury in specific settings 
and diagnosing unexpected aetiologies
Several situations or settings deserve particular attention. 
In addition, some patients may present with AKI without 
associated manifestations or obvious predisposing fac-
tors. In these patients, a basic diagnostic work-up should 
be performed to avoid missing specific types of AKI 
(Fig. 3). This also applies to AKI in transplant recipients 
(Table  2). Additionally, several ICU conditions, includ-
ing prolonged and complex surgery, comatose states or 
status epilepticus, and exposure to some drugs such as 
cocaine and envenomation may predispose to rhabdomy-
olysis [36]. To ensure prompt implementation of preven-
tive measures, measuring creatinine kinase levels should 
be part of the routine testing in such high-risk patients. 
Last, intensivists should be aware of differential diagno-
sis of AKI in specific conditions such bile acid-induced 
cholemic nephropathy in patients with advanced liver 
disease and AKI unresponsive to vasopressin analog [37].
Acute glomerulonephritis—systemic diseases: vasculitis
Acute glomerulonephritis or rapidly progressive glo-
merulonephritis (RPGN) are rare forms of renal diseases 
manifesting by a sub-acute and progressive rise in serum 
creatinine. In the majority of cases, RPGN is encountered 
in the context of systemic diseases with multiple organ 
involvement. The pathological lesion of RPGN is extra-
capillary glomerular proliferation (crescents). The usual 
classification is based on immunofluorescence examina-
tion of the glomerulus [38]. Goodpasture’s disease is due 
to antibodies directed against the glomerular basement 
membrane (GBM). It typically presents as RPGN and 
intra-alveolar haemorrhage. Immunofluorescence exami-
nation shows linear deposition of IgG along the GBM.
Immune complex diseases are characterized by 
granular deposits of various immunoglobulins and 
complement fractions. Several diseases share this presen-
tation, including systemic lupus erythematosus, Henoch–
Schönlein purpura, cryoglobulinemia and post-infectious 
glomerulonephritis (in particular endocarditis). Lastly, 
pauci-immune glomerulonephritis is characterized by 
the absence of immune deposits on immunofluorescence 
and is associated with antineutrophil cytoplasmic anti-
bodies (ANCA)-positive vasculitides.
Although RGPN is uncommon in ICU patients, its 
exact prevalence remains unknown. Outside the ICU 
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setting, a study showed that acute glomerulonephritis 
was diagnosed in 5.6% of 748 patients admitted over a 
year in a nephrology unit [39]. Frequency may rise up to 
31% in patients aged 65 years or older [40]. Among ICU 
patients undergoing a renal biopsy, RGPN was observed 
in 25% of cases [31]. Finally, in a recent study on 363 
patients admitted to the ICU with rheumatic disease, 
one-third of them were admitted for disease activity and 
less than 10% for RGPN [41]. In this subset of patients, 
ANCA-associated vasculitis were the most frequent dis-
eases [41]. Studies on ANCA-associated vasculitis in ICU 
patients showed a higher incidence of granulomatosis 
with polyangiitis than microscopic polyangiitis [42].
Patient and renal outcomes depend on rapid initiation 
of a specific treatment. The combination of a low inci-
dence, an acute presentation mimicking more frequent 
pathologies, and the need for emergent specific treatment 
make RPGN diagnosis particularly challenging in ICU 
patients. RPGN are classically characterized by devel-
opment of AKI or AKD over a period of days to a few 
weeks, arterial hypertension, proteinuria and haematuria. 
Hypertension may be absent especially in ICU patients, 
and proteinuria and haematuria are often non-specific. 
[43]. Acute respiratory failure with lung consolidation 
and rising serum creatinine (the so-called “pulmonary-
renal syndrome”) may occasionally be due to RGPN 
and intra-alveolar haemorrhage associated with vascu-
litis [44]. Non-renal symptoms evocative of systemic 
diseases including weight loss, symptoms lasting over 
several weeks, haemoptysis with anemia, arthritis, skin 
involvement, sinusitis and peripheral neurologic disease 
Fig. 3 First-line diagnostic work-up in patients with AKI without obvious predisposing factor
Table 2 Complications not to be missed in renal transplant 
recipients with AKI
AKI acute kidney injury, GN glomerulonephritis, TMA thrombotic 
microangiopathy, HUS hemolytic and uremic syndrome, aHUS atypical HUS
To do list What should I search for?
Renal hypoperfusion (a) Absolute hypovolemia
(b) Cardiac dysfunction
(c) Renal vasoconstriction
  Acute anticalcineurin intoxication
  Renal graft artery stenosis ± renin angiotensin 
system antagonists
  Hepato-renal syndrome
Post-renal AKI (a) Empty bladder
  With ureteral dilation: fibrosis of the uretero-
vesical anastomosis; obstructive lithiasis; fungus 
ball; papillary necrosis
  Without ureteral dilation: pyelo-ureteral stenosis; 
compression ± super-imposed infection
(b) Dilated bladder: low obstacle or cervico-
uretral
Intrinsic AKI
Renal biopsy usually 
required
(a) Acute interstitial and/or tubular nephritis
  Acute cellular rejection
  Sepsis
  Acute pyelonephritis
  BK virus nephropathy (haematuria+++)
  Anticalcineurin intoxication
  Recurrence of oxalate deposition (hyperoxaluria)
(b) Glomerular disease (high proteinuria, mainly 
albuminuria)
  Recurrence of underlying nephropathy
  De novo glomerular injury (humoral rejection; 
membranous GN)
(c) Vascular disease
  TMA (recurrence of aHUS, de novo HUS, hyper-
acute rejection)
  Herpes viridae infection
  Recurrence of vasculitis (ANCA-associated)
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are important clues that should alert the ICU physician 
[31, 44]. The diagnosis of RPGN relies on examination 
of a renal biopsy, which in this case is a medical emer-
gency. However, alternate diagnostic approaches based 
on immunological blood assays may be preferred when 
available. An evocative clinical picture should prompt the 
measurement of ANCA, anti-GBM antibodies, cryoglo-
bulins, anti-nuclear and anti-DNA antibodies and com-
plement fractions C3, C4 and CH50. It must be noted, 
however,that these auto-antibodies should be interpreted 
cautiously since low titres can be observed in inflamma-
tory conditions.
In ICU patients with suspected vasculitis, urgent 
treatment is required. In case of probable or confirmed 
Goodpasture disease or ANCA-associated vasculitis, 
treatment with steroids, cyclophosphamide and plasma 
exchange is often required. Although the efficacy of anti-
CD20 antibodies (i.e. Rituximab) has been demonstrated, 
its clinical usefulness in ICU patients remains uncertain 
[45, 46].
Acute interstitial nephritis
Acute interstitial nephritis (AIN) accounts for 10–25% 
of biopsy-proven AKI and should be considered one of 
the frequently missed AKI diagnoses in the ICU [28, 
47, 48]. It is a histological diagnosis characterized by 
infiltration of inflammatory cells within the renal inter-
stitium with sparing of the glomeruli and blood vessels. 
AIN can evolve to interstitial fibrosis within 7–10 days 
[28, 47, 48]. The most frequent causes of AIN are drugs, 
primary renal infections such as acute bacterial pyelo-
nephritis, inflammatory disorders such as systemic 
lupus, Sjögren’s syndrome and sarcoidosis, or neoplastic 
diseases. Any drug can cause AIN, but antibiotics, non-
steroidal anti-inflammatory drugs and proton-pump 
inhibitors are the most common medications associated 
with AIN. Drug-induced AIN can manifest at any stage 
after starting the medication and is not usually dose-
related [49].
In critically ill patients with AIN, classical symptoms 
are usually absent. The presence of a rash, eosinophilia 
or eosinophiluria in a patient with AKI may be sugges-
tive of AIN, and although insufficient to confirm diagno-
sis, should raise ICU physician awareness. Renal biopsy is 
the only definitive method of establishing the diagnosis. 
New diagnostic tests are urgently needed to improve AIN 
diagnosis, especially in critically ill patients [47].
Management of AIN consists of withdrawal of offend-
ing medications and treatment of an underlying inflam-
matory disease. Although the use of corticosteroids 
remains controversial, delayed initiation of steroids has 
been associated with incomplete renal recovery. There-
fore, it is reasonable to use corticosteroids when there is 
no improvement within 3–7 days after discontinuation of 
the offending drug [47, 48].
AKI in haematological patients
Critically ill cancer patients seem at higher risk of devel-
oping AKI [50, 51]. Although most of the AKI episodes 
are multifactorial, specific causes may deserve urgent 
therapies. Thus, cancer patients may develop obstruc-
tive diseases and are more prone to nephron loss due to 
nephrectomy, nephrotoxic agents or previous AKI epi-
sodes [52].
Tumor lysis syndrome (TLS) may arise as result of 
rapid destruction of malignant cells leading to the release 
of intracellular ions, proteins, and metabolites into the 
extra-cellular space [53]. Although TLS usually occurs in 
patients with extensive, rapidly growing, chemosensitive 
malignancies, TLS has also been described in patients 
with low-grade malignancy treated with targeted thera-
pies. The diagnostic criteria of TLS have been recently 
standardized (Table S1) [54]. Accordingly, a constellation 
of metabolic disturbances (hyperkalaemia, hyperphos-
phataemia, hypocalcaemia, and hyperuricaemia) defines 
laboratory TLS in high-risk patients, while clinical mani-
festations (cardiac, renal or neurological manifestations 
of TLS) in patients with laboratory TLS defines clinical 
TLS [54]. TLS may occur rapidly. Frequent (up to every 
6 h) and routine search for metabolic disturbances, along 
with preventative measures, including hydration and 
treatment with urate oxidase, are mandatory [54].
In patients with myeloma, cast nephropathy remains 
the most common cause of renal injury, and reversibil-
ity may be achieved in up to 60% of these patients with 
immediate initiation of appropriate therapy [55, 56]. Cast 
nephropathy is caused by the precipitation of monoclonal 
light chains which bind Tamm Horsfall protein causing 
tubular obstruction. High amounts of Bence Jones pro-
teinuria, extreme κ/λ light chain ratios or high serum lev-
els of free light chains are suggestive of cast nephropathy 
[57, 58]. In some patients, renal biopsy may be avoided 
since cast nephropathy is the most common pathol-
ogy, especially if urine albumin excretion is low (<25%) 
[59]. Early detection of cast nephropathy, combined with 
urgent chemotherapy, may improve the chances of renal 
recovery [55]. Bortezomib-based combinations are con-
sidered the most effective therapy for patients with AKI 
due to cast nephropathy, and should start as soon as pos-
sible [55]. The role of plasmapheresis is not established, 
and renal replacement therapy with high cut-off mem-
branes (with cut-off around 50 kDa) might decrease free 
light chain concentrations [60]. Two prospective studies 
have recently shown conflicting results on the poten-
tial benefits of such an approach in patients with cast 
nephropathy [61, 62], and further analysis is required to 
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identify which patients may get the maximum benefit 
from this demanding approach.
In patients with haemolytic anemia and thrombocy-
topenia, thrombotic microangiopathy (TMA) should be 
ruled out. Although rare, the combination of microan-
giopathic anaemia [non-immune haemolytic anaemia 
due to mechanical damage of red blood cells and result-
ing in high plasma lactate dehydrogenase (LDH) levels] 
with peripheral thrombocytopenia suggests this syn-
drome [63, 64]. The presence of damaged red blood cells 
(schistocytes) on peripheral blood smears confirms the 
microangiopathy. Differential diagnoses include auto-
immune cytopenia and infectious causes of microan-
giopathic anaemia (malaria, babesiosis). Various organ 
dysfunctions may occur related to small vessel obstruc-
tion [63, 64]. Although overlap may occur, renal injury is 
more frequent in patients with haemolytic uremic syn-
drome (HUS), while neurological dysfunction is more 
common in patients with thrombotic thrombocytopenic 
purpura (TTP, also known as Moschowitz syndrome) 
[63, 64]. Three main syndromes should be searched for, 
including diarrhoea-associated HUS, usually associ-
ated with Shiga toxin-producing E. coli [63, 64], atypical 
HUS (aHUS) which is usually complement-mediated and 
associated with congenital abnormalities of the alterna-
tive complement pathway regulation [63–65] and TTP 
which is related to congenital or acquired ADAMTS13 
deficiency [62, 63]. In patients suspected of either aHUS 
and TTP, looking for congenital complement abnormali-
ties, measuring ADAMTS13 activity and looking for anti-
ADAMTS13 antibodies should be the rule [62, 63].
AKI in the obstetric setting
In the developed world, the incidence of AKI during preg-
nancy, currently estimated around 1/20,000 pregnancies, 
has substantially decreased due to better prenatal care 
and reduction of illegal abortion. The diagnosis of obstet-
ric AKI may be masked by the physiological increase of 
GFR (up to 40%). Obstruction by the gravid uterus may 
cause obstructive AKI, the diagnosis of which is compli-
cated by physiological hydronephrosis and hydroureter. 
AKI during pregnancy is often multifactorial with both 
pregnancy-related and other potential causes. Timing 
may help in the differential diagnosis (Figure S1) [65]. 
In the early phase, sepsis (pyelonephritis, septic abor-
tion) and hypovolemia (hyperemesis gravidarum, haem-
orrhage) are the most common causes, whereas in the 
later phase haemorrhage (abruptio placentae, postpar-
tum haemorrhage), sepsis and typical pregnancy-related 
complications predominate. Preeclampsia, a poorly 
understood systemic disorder due to dysregulation of 
angiogenic factors, characterized by hypertension and 
proteinuria, or its variant Hemolysis with Elevated Liver 
tests and Low Platelets (HELLP), typically develop during 
the third trimester. The TMA include aHUS, that more 
commonly begins peri- and post-partum, and TTP, which 
develops in the second and third trimester. Pregnancy 
predisposes to TTP due to a decrease of ADAMTS-13 
activity and increase of von Willebrand factor concentra-
tions, but may also be a triggering factor for aHUS (due 
to dysregulation of the alternative complement pathway). 
Acute fatty liver of pregnancy (AFLP), caused by foetal 
and maternal congenital defects in beta-oxidation of fatty 
acids, is a rare but life-threatening cause of pregnancy-
related AKI that mostly occurs close to term. Other 
potential causes of peripartum AKI include amniotic 
fluid embolism or cardiomyopathy.
Differentiating HUS/TTP from HELLP and AFLP is chal-
lenging but vital because of the therapeutic consequences 
[66–68]. An adequate differential diagnosis requires care-
ful history including timing of onset, clinical examination, 
drug review, dipstick and microscopic urine examination, 
proteinuria, haemoglobin level, platelet counts, peripheral 
blood smears, LDH, coagulation tests, bilirubin, transami-
nases, blood glucose levels, ADAMTS-13 activity, comple-
ment factors and ultrasound (Table S2).
Acute kidney injury in low and middle income countries
In low and middle income countries (LMIC), early pre-
ventive and therapeutic measures are the key way to 
decrease morbidity, mortality and cost (Table  3). Early 
detection of AKI is impaired by limited diagnostic assets 
and poor understanding of the condition [69]. Such lim-
ited understanding—to a large extent determined by 
inadequate reporting and education—limits awareness 
and early recognition and delays the implementation of 
adequate management [70]. In LMIC, the common lack 
of access to specialized nephrology care requires that 
AKI be understood and recognized at all levels of the 
healthcare system [71]. A practical and easily accessible 
educational strategy focused on providers at the forefront 
of healthcare delivery (including primary physicians, 
nurses and community healthcare providers) is indispen-
sable to achieve this goal [72].
In the community, in areas where infectious diseases 
such as severe malaria, leptospirosis or dengue are 
endemic and associated with high rates of AKI, a febrile 
patient should elicit concern for renal injury [73]. Simi-
larly, in patients with severe volume depletion due to gas-
trointestinal loss, volume resuscitation is central to care 
and to prevent renal injury—preferably before the onset 
of persistent oliguria [72]. In some areas of the world, 
exposure to snake venom represents a frequent cause of 
AKI. Administration of herbs by traditional healers has 
been associated with nephrotoxicity and must be consid-
ered when confronted with AKI of unclear aetiology [74]. 
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Increased availability and use of over-the-counter medi-
cations such as NSAIDs significantly contribute to a ris-
ing incidence of AKI.
The development of AKI as a maternal and neonatal 
complication is especially important in the LMIC envi-
ronment [74], where failure to recognize renal injury fre-
quently leads to significant consequences for mother and 
child. In this area, successful efforts to improve early rec-
ognition have clearly demonstrated benefit—especially 
by reducing some of the more dreaded consequences 
such as cortical necrosis [75].
Conversely, in the LMIC hospital and ICU settings, 
AKI recognition faces challenges akin to those seen in 
the developed world; among hospitalized patients, AKI 
related to exposure to nephrotoxic medications, antibiot-
ics, intravascular administration of iodinated radiocon-
trast and surgical procedures is very common. Especially 
in the LMIC setting, additional testing and urinary 
microscopy are necessary to identify the underlying etiol-
ogy. The performance of basic urine microscopy focusing 
on the presence of erythrocytes, leukocytes, eosinophils 
and casts in the sediment is invaluable to assess the ini-
tial presentation of the patient with AKI [76]. Training in 
microscopic urine examination and availability of basic 
examination equipment for such testing should be pro-
moted as a key, low-resource test for detection of AKI in 
LMIC. Point of care testing (POCT) for creatinine meas-
urements can be performed by non-laboratory-trained 
individuals, thus eliminating delays in testing and report-
ing of results [77]. However, it requires the implementa-
tion of a quality assurance program that ensures accurate 
and reliable results. Last, kidney biopsies in patients with 
AKI are more common in LMIC than in HIC and, thus, 
there is a greater appreciation of the relative incidence 
of multiple aetiologies and the value of a renal biopsy to 
guide management [69].
Conclusion and future directions
Identifying and diagnosing specific causes of AKI in criti-
cally ill patients remains challenging. A high degree of 
suspicion must be the rule and a systematic diagnostic 
work-up should be undertaken in every AKI presenting 
without an obvious predisposing factor or following an 
unusual course. Although data regarding specific causes 
of AKI remain limited, increased recognition of the 
nephrotoxic contribution to AKI [78], and of the infre-
quent finding of true “acute tubular necrosis” in critically 
ill patients, will result in improved AKI management 
[79–81].
It may be time to search more closely for specific 
causes, assess more carefully the prevalence of aeti-
ologies even when typical symptoms are misleadingly 
absent—such as acute post-infectious glomerulonephritis 
or AIN—and, ultimately, reshape an old-fashioned and 
probably outdated AKI diagnostic paradigm.
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Table 3 The contrasting characteristics of AKI around the world
Modified from [69, 74]
AKI in high-income countries AKI in low and middle-income countries
Pattern of occurrence Occurs predominantly in intensive care units Occurs in rural health centres and hospitals as well as in large urban hospitals
Disease patterns Associated with multiple organ failure Often caused by a single disease; multiple organ failure less common
Associations Associated with sepsis and complex surgery Frequently associated with specific diseases and endemic infections
Mortality High mortality Similar or higher mortality than high-income countries
Populations affected A disease of elderly populations A disease of otherwise healthy children and young persons
Incidence Increasing incidence Increasingly recognized high incidence
Reporting Adequately reported Severely underreported
Preventable status Difficult to prevent Preventable, generally with public health initiatives
Cost Very expensive to treat Very inexpensive to treat at early stages; unaffordable in severe stages
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